The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 05, 2018
Filed:
Apr. 27, 2012
Applicants:
Christopher Fraser, Arlington, MA (US);
Takashi Kei Kishimoto, Lexington, MA (US);
Roberto A. Maldonado, Jamaica Plain, MA (US);
Inventors:
Christopher Fraser, Arlington, MA (US);
Takashi Kei Kishimoto, Lexington, MA (US);
Roberto A. Maldonado, Jamaica Plain, MA (US);
Assignee:
Selecta Biosciences, Inc., Watertown, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/38 (2006.01); A61K 39/005 (2006.01); A61K 47/48 (2006.01); A61K 39/385 (2006.01); A61K 39/35 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); B82Y 5/00 (2011.01); A61K 39/36 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 31/192 (2006.01); A61K 9/14 (2006.01); A61K 38/13 (2006.01); A61K 38/18 (2006.01); A61K 47/50 (2017.01); A61K 47/52 (2017.01); A61K 47/54 (2017.01); A61K 47/59 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); B82Y 40/00 (2011.01);
U.S. Cl.
CPC ...
A61K 39/385 (2013.01); A61K 9/127 (2013.01); A61K 9/14 (2013.01); A61K 9/51 (2013.01); A61K 9/5115 (2013.01); A61K 9/5146 (2013.01); A61K 9/5153 (2013.01); A61K 31/192 (2013.01); A61K 38/13 (2013.01); A61K 38/1816 (2013.01); A61K 38/38 (2013.01); A61K 39/00 (2013.01); A61K 39/001 (2013.01); A61K 39/0008 (2013.01); A61K 39/35 (2013.01); A61K 39/36 (2013.01); A61K 47/50 (2017.08); A61K 47/52 (2017.08); A61K 47/544 (2017.08); A61K 47/593 (2017.08); A61K 47/643 (2017.08); A61K 47/69 (2017.08); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 47/6937 (2017.08); B82Y 5/00 (2013.01); G01N 33/505 (2013.01); G01N 33/56972 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/577 (2013.01); B82Y 40/00 (2013.01); G01N 2333/7051 (2013.01); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01);
Abstract
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).